Contrafect Corp (CFRX)

[noretreat]

here's something...not about the warrants, but....stock is down today because of the offering. May be a good place to add.

Every year the biotech showcase is an excellent chance to discover investment opportunities and to conduct due diligence. This year's showcase was no exception, even though the near term share price outlook seems bleak for biotech in general. Many of the companies I'm going to mention have already seen 50% share price drops. Some much more than that. As I write this today (January 20), the IBB index is at 276, off from its 52-week high of 400 last July.

In my view, current conditions are an opportunity. "Babies are being thrown out with the bathwater". Here are some examples.

----etc----

Contrafect

Another interesting anti-infective company is Contrafect. Their lead product, CF-301, may work better than current treatments against some of the worst infections, including staph bacteremia. In combination with Daptomycin and Vancomycin there appears to be a significant increase in efficacy and limited additional side effects.

Contrafect has a number of other products, including a promising drug cocktail combining 3 monoclonal antibodies for many strains of influenza.

The stock is trading a bit over $4 right now, down from $6.24 last April. The company raised $20 million in a private placement last June, and announced a $30 million ATM offering after the close today. There is plenty of funding here.

-----etc-----